High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer

BMC Cancer

Table 3 Hazard ratio of PSA recurrence-free survival of established prognostic parameters and BCAR1 expression

	Scenario	1	2	3	4
	Analyzable (N)	8522	8662	8778	5362
Preoperative	Gleason score biopsy
	3 + 4 vs. ≤3 + 3	1.98 ^***
	4 + 3 vs. 3 + 4	1.62 ^***
	≥ 4 + 4 vs. 4 + 3	1.30 ^***
	Clinical tumor (cT) stage
	T2a vs. T1c	1.33 ^***	1.33 ^***
	T2b vs. T2a	1.47 ^***	1.40 ^***
	T3a vs. T2c	0.62 ^*	0.65 ^*
	Preoperative PSA level
	4–10 vs. <4	1.45 ^***	1.38 ^**	1.21 ^*	1.17
	10–20 vs. 4–10	1.52 ^***	1.43 ^***	1.28 ^***	1.19 ^*
	> 20 vs. 10–20	1.69 ***	1.53 ***	1.20 *	1.19 ^*
	BCAR1 expression
	Weak vs. negative	1.17 ^*	1.14	1.16 ^*	1.29 ^*
	Moderate vs. weak	0.91	0.92	0.88	0.78 *
	Strong vs. moderate	1.14 ^*	1.08	1.12	1.13
Postoperative	Gleason score prostatectomy
	3 + 4 vs. ≤3 + 3		3.05 ^***	2.48 ^***	2.24 ^***
	4 + 3 vs. 3 + 4		2.56 ^***	2.13 ^***	2.01 ^***
	≥ 4 + 4 vs. 4 + 3		1.70 ^***	1.20 ^*	1.11
	Pathological tumor (pT) stage
	T3a vs. T2			2.00 ^***	2.03 ^***
	T3b vs. T3a			1.72 ^***	1.55 ^***
	T4 vs. T3b			1.38 ^*	1.35
	Surgical margin (R) status
	R1 vs. R0			1.44 ^***	1.31 ^***
	Lymph node (N) status
	N+ vs. N0				1.44 ^***

Scenario 1 combines preoperatively available parameter (preoperative Gleason score obtained on the original biopsy, clinical tumor (cT) stage, and preoperative PSA) with the postoperative BCAR1 expression. In scenario 2 the biopsy Gleason is replaced by the Gleason score obtained on radical prostatectomy (RPE). In scenario 3 cT-stage is superseded by pathological tumor (pT) stage and surgical margin (R) status. In scenario 4 the lymph node (pN) stage is added. Asterisk indicate significance level: * p ≤ 0.05, ** p ≤ 0.001, and *** p ≤ 0.0001

ISSN: 1471-2407